Mouse paw edema induced by a novel bradykinin agonist and its inhibition by B2-antagonists.

Abstract

A novel non-peptide bradykinin B2-receptor agonist, FR190997 (8-[2,6-dichloro-3-[N-[(E)4-(N-methylcarbamoyl)cinnamidoacetyl+ ++]-N-methylamino]benzyloxy]-2-methyl-4-(2-pyridylmethoxy)quinolin e), induced dose-dependent and longer-lasting swelling than bradykinin in the mouse paw. The swelling, peaking around 30 min, was suppressed dose-dependently by intraperitoneal administration of FR173657, a novel non-peptide B2-receptor antagonist. A known B2-antagonist, Hoe 140, also significantly suppressed this edema. The result indicates that the novel B2-agonist FR190997, being more stable than bradykinin, could induce plasma exudation locally in mice via the B2-receptor as a substitute for bradykinin.

• Authors: A Ueno, H Naraba, S Oh-ishi
• Journal: Japanese journal of pharmacology (Jpn J Pharmacol) Vol. 78 Issue 1 Pg. 109-11 (Sep 1998) ISSN: 0021-5198 [Print] Japan
• PMID: 9804073 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Bradykinin Receptor Antagonists
• FR 173657
• FR 190997
• Quinolines
• Receptors, Bradykinin
• icatibant
• Bradykinin

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
• Bradykinin (analogs & derivatives, pharmacology)
• Bradykinin Receptor Antagonists
• Dose-Response Relationship, Drug
• Edema (chemically induced, pathology, prevention & control)
• Foot (pathology)
• Hindlimb
• Male
• Mice
• Mice, Inbred ICR
• Quinolines (pharmacology)
• Receptors, Bradykinin (agonists)